Skip to main content
Clinical Trials/NCT07350473
NCT07350473
Not yet recruiting
Not Applicable

Vibration-Assisted Physical Activity for Glycaemic Control in Type-2 Diabetes: A Randomised Controlled Trial in the Kingdom of Saudi Arabia

University of Central Lancashire0 sites305 target enrollmentStarted: December 1, 2026Last updated:

Overview

Phase
Not Applicable
Status
Not yet recruiting
Enrollment
305
Primary Endpoint
HBA1c (Glycated hemoglobin)

Overview

Brief Summary

The World Health Organization ranks Saudi Arabia as having the 7th highest rate of type-2 diabetes in the world. This therefore makes diabetes the most challenging health problem facing Saudi Arabia. Importantly, physical activity has been shown to improve disease symptoms and overall health in patients with type-2 diabetes. However, findings relating to the prevalence of physical inactivity in the Saudi population confirm that a sedentary lifestyle is on the rise, within physical inactivity levels in adults being 80.5%. Therefore, interventions aimed at reducing physical inactivity using bespoke modalities pertinent to Saudi Arabia are clearly warranted.

There have been no fully powered, placebo-controlled trials of localised wearable calf vibration in T2DM within the Kingdom of Saudi Arabia. The proposed study will address this gap by evaluating a 12 week, home based, seated calf vibration intervention in Saudi adults with T2DM, recruited from the Jazan Diabetes and Endocrinology Center. A three-arm design will compare active localised vibration, a sham vibration condition and usual care.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Single (Participant)

Eligibility Criteria

Ages
18 Years to 65 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Clinically established diagnosis of type-2 diabetes for at least 12 months
  • Previously sedentary
  • Knowledgeable about hypoglycaemia
  • Aged over 18 years
  • Capacity to give informed consent.

Exclusion Criteria

  • Cognitive impairment precluding consent or participation
  • Pregnancy
  • Additional medical conditions that prevent safe physical activity (e.g. severe arthritis or advanced heart failure)
  • Enrolment in any other clinical trial designed to influence type-2 diabetes symptoms.

Arms & Interventions

Localized Vibration

Experimental

Intervention: Localized vibration (Device)

Placebo vibration

Sham Comparator

Intervention: Placebo vibration (Other)

Usual care

Other

Intervention: Usual care (Other)

Outcomes

Primary Outcomes

HBA1c (Glycated hemoglobin)

Time Frame: Baseline

Glycated hemoglobin is a form of hemoglobin that is chemically linked to a sugar. This parameter will be obtained via a venous blood sample.

HBA1c (Glycated hemoglobin)

Time Frame: 12 weeks

Glycated hemoglobin is a form of hemoglobin that is chemically linked to a sugar. This parameter will be obtained via a venous blood sample.

Secondary Outcomes

  • WHO Well-Being Index (WHO-5)(Baseline)
  • WHO Well-Being Index (WHO-5)(12 weeks)
  • Patient Health Questionnaire-9 (PHQ-9)(Baseline)
  • Patient Health Questionnaire-9 (PHQ-9)(12 weeks)
  • Pittsburgh Sleep Quality Index (PSQI)(Baseline)
  • Pittsburgh Sleep Quality Index (PSQI)(12 weeks)
  • Physical fitness(Baseline)
  • Physical fitness(12 weeks)
  • Fasting glucose(Baseline)
  • Fasting glucose(12 weeks)
  • Systolic blood pressure(Baseline)
  • Systolic blood pressure(12 weeks)
  • Diastolic blood pressure(Baseline)
  • Diastolic blood pressure(12 weeks)
  • Body mass(Baseline)
  • Body mass(12 weeks)
  • Body mass index(Baseline)
  • Body mass index(12 weeks)
  • Triglyceride-glucose index(Baseline)
  • Triglyceride-glucose index(12 weeks)
  • Total cholesterol(Baseline)
  • Total cholesterol(12 weeks)
  • HDL cholesterol(Baseline)
  • HDL cholesterol(12 weeks)
  • LDL cholesterol(Baseline)
  • LDL cholesterol(12 weeks)
  • Triglycerides(Baseline)
  • Triglycerides(12 weeks)
  • Single Leg Stance(Baseline)
  • Single Leg Stance(12 weeks)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Jonathan Sinclair

Professor

University of Central Lancashire

Similar Trials